Skip to content
ETEN
Findshops
Science & Health

Clinical Trial: THC and CBD Combination Relieved Migraine More Effectively Than Placebo

Illustrative medical research photograph, not the migraine trial

A randomised, double-blind, placebo-controlled clinical trial in acute migraine found that a vaporized THC and CBD combination relieved migraine attack symptoms significantly more effectively than placebo. Two hours after administration, pain relief occurred in 67.2% of combination treatment sessions, compared with 46.6% of placebo sessions.

Updated November 2026. When 420Eesti first reported this research in 2025, the findings had been presented at a scientific conference and as a preprint. The study has since appeared in the peer-reviewed journal Headache (online on 30 December 2025; in a 2026 journal issue).

What did the researchers study?

Illustrative medical research photograph by Edward Jenner, not the reported trial
Illustrative medical research photograph, not the reported clinical trial. Photo: Edward Jenner / Pexels.

The University of California San Diego study involved 92 adults with migraine. A total of 247 migraine attacks were treated during the trial. For different attacks, participants received vaporized cannabis flower in a random order under four conditions: 6% THC, 11% CBD, a combination of 6% THC and 11% CBD, or placebo. There was at least a week between treated attacks.

It was the first trial of this design to compare these cannabinoid preparations with placebo specifically for an acute migraine attack. Outcomes included pain relief, complete freedom from pain and freedom from the patient’s most bothersome associated symptom.

The main findings

With the THC and CBD combination, pain relief at two hours occurred in 67.2% of treatment sessions, compared with 46.6% with placebo. Complete pain freedom occurred in 34.5% versus 15.5%. Freedom from the most bothersome associated symptom occurred in 60.3% versus 34.5%, respectively.

The THC-only condition also produced pain relief more frequently than placebo (68.9% versus 46.6%), but was not statistically superior for complete pain freedom at two hours. The CBD-only condition did not outperform placebo in the primary two-hour analysis.

Several measures suggested that benefits of the THC and CBD combination continued into the following day: sustained pain freedom at 24 hours was more common than with placebo, as was freedom from the most bothersome symptom at 48 hours. These findings give researchers an important reason to investigate cannabinoid combinations further.

Why does this finding matter?

Migraine involves more than a headache. It can include light and sound sensitivity, nausea and a reduced ability to work or study. Some patients do not obtain adequate relief from existing medicines, making research into treatments with different mechanisms important.

The study provides an initial controlled clinical signal that a specific vaporized preparation containing THC and CBD may help during an acute migraine attack. It is a clinical trial with several treatment conditions, rather than an account of online users’ experiences.

What did the trial not compare?

The study did not compare cannabinoids with triptans or other conventional migraine medicines. It therefore cannot show that THC and CBD worked faster or better than those treatments. Nor did it investigate the long-term effectiveness or safety of repeated daily use.

No serious adverse events were recorded in the trial, but this does not establish an absence of risk in a larger patient population. THC can affect attention and reaction times, so the results should not be turned into a recommendation for self-treatment.

What comes next?

The findings are encouraging for cannabis research. The next step is larger independent trials comparing standardised cannabinoid preparations with existing migraine medicines and assessing the effects of repeated use.

Original source: Schuster et al., ‘Vaporized cannabis versus placebo for acute migraine’, Headache (2026), DOI 10.1111/head.70025.

For other studies and limitations of medical cannabis, see our overview of migraine and cannabinoids. One clinical trial does not mean that cannabis is a suitable treatment for everyone with migraine.

Sources

Share article
REKLAAMIPIND
Your ad here

Advertising space available.

Get in touch ↗

Lisa kommentaar

Your email address will not be published. Required fields are marked *